跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD276 CAR-T cells
首页
药物
CD276 CAR-T cells
CD276 CAR-T cells
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
IGG DERIVED B7-H3-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (B7-H3 CAR) EFFECTOR CELLS FOR THE TREATMENT OF CD276+ TUMORS AND AUTOIMMUNE DISEASES
US 20260209356 A1
申请人: OSPEDALE PEDIATRICO BAMBINO GESÙ
优先权: 2022
EP
US
WO
3 件公开
ANTIBODY SPECIFICALLY BINDING TO CD276, PREPARATION METHOD THEREFOR AND USE THEREOF
EP 4703386 A1
申请人: SHANGHAI SINOBAY BIOTECHNOLOGY CO LTD
优先权: 2023
CN
EP
WO
3 件公开
Chimeric antigen receptor based on CD276 antibody, lentivirus expression vector and application thereof
CN 109929039 A
申请人: FIRST AFFILIATED HOSPITAL ZHENGZHOU UNIV
优先权: 2019
CN
Rapid preparation process of CD276 CAR-T cell and CD276 CAR-T cell
CN 119242713 A
申请人: SHANGHAI HRAIN BIOTECHNOLOGY CO LTD
优先权: 2023
CN
EXTRACELLULAR VESICLES DERIVED FROM STIMULATED CAR-T CELLS
WO 2025115008 A1
申请人: ICHILOV TECH LTD
优先权: 2023
WO
IMMUNE EFFECTOR CELL EXPRESSING CHIMERIC ANTIGEN RECEPTOR TARGETING GPC3 AND CHIMERIC RECEPTOR TARGETING CD276, AND USES THEREOF
WO 2025183436 A1
申请人: INNOBATION BIO CO LTD
优先权: 2024
WO
CAR-T cell driven by different promoters and targeting CD276 and application of CAR-T cell
CN 121320396 A
申请人: PERSONGEN BIOMEDICINE SUZHOU CO LTD
优先权: 2024
CN
药物
反馈